Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 2	2026-08-12		NCT06263543

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Gilead Sciences	180
Reshma L. Mahtani, D.O.	1

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Baptist Health Herbert Wertheim Cancer Institute	Miami	United States	3
University of Kansas Medical Center	Fairway	United States	18
Winship Cancer Institute At Emory University	Atlanta	United States	10

Clinical trials